Cargando…

Cytotoxic and Apoptotic Effects of Pinostilbene and Bortezomib Combination Treatment on Human Multiple Myeloma Cells

Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow characterized by bone lesions, hypercalcemia, anemia, and renal failure. Bortezomib (BTZ), a common treatment for MM, is a proteasome inhibitor that induces apoptosis in MM cells. However, high doses of BTZ can be very toxic, signi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staskiewicz, Anna, Wong, Erica, Tucker, Michael, Farhin, Riya, Park, Jonathan, Saade, Rana, Alkhazali, Tina, Dang, Tu, Wang, Xinyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454535/ https://www.ncbi.nlm.nih.gov/pubmed/37628771 http://dx.doi.org/10.3390/ijms241612590

Ejemplares similares

Rational Design of Resveratrol O-methyltransferase for the Production of Pinostilbene
por: Herrera, Daniela P., et al.
Publicado: (2021)

Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
por: Starheim, K K, et al.
Publicado: (2016)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer
por: Shin, Won Sik, et al.
Publicado: (2023)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma
por: Yang, Min Hee, et al.
Publicado: (2019)

Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma
por: Ghasemi, Mehdi, et al.
Publicado: (2016)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

Inhibitory Effects of Pinostilbene on Adipogenesis in 3T3-L1 Adipocytes: A Study of Possible Mechanisms
por: Chung, You Chul, et al.
Publicado: (2021)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011)

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013)

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib
por: Zhao, Yinghao, et al.
Publicado: (2015)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
por: Chen, Wendong, et al.
Publicado: (2016)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria
por: Korubo, Kaladada I., et al.
Publicado: (2017)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
por: Zaal, Esther A., et al.
Publicado: (2017)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
por: Robak, Paweł, et al.
Publicado: (2020)

The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma
por: Nikesitch, Nicholas, et al.
Publicado: (2021)

Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma
por: Paterek, Aleksandra, et al.
Publicado: (2023)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
por: Wong, Kwan Yeung, et al.
Publicado: (2013)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

Bortezomib a Safe Treatment for Patients with Multiple Myeloma and Cystic Fibrosis
por: Gentilini, Fabiana, et al.
Publicado: (2012)

The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma
por: Yi, Yang-Seon, et al.
Publicado: (2010)

A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
por: Kim, Youngwoon, et al.
Publicado: (2012)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7fuekknj58tdl1vbmfqj6kvfb4